Randomised controlled trial
STEP-1
Wilding JPH et al., NEJM 2021;384:989–1002
- Participants
- 1,961
- Duration
- 68 weeks
- Comparator
- vs. placebo, alongside lifestyle intervention
Participants on semaglutide 2.4 mg weekly lost an average of ~14.9% of baseline body weight versus ~2.4% on placebo. Trial participants had BMI ≥ 30, or ≥ 27 with a weight-related comorbidity.
Read the full paper
